Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 6/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29112713 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 | |
| SCHEMBL30887346 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 | |
| SCHEMBL28369074 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 | |
| SCHEMBL7316714 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 | |
| SCHEMBL29510761 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1ACES1CYP2C19NPC1 | |
| SCHEMBL26127150 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 | |
| SCHEMBL8153532 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 | |
| SCHEMBL5235928 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 | |
| SCHEMBL73702 | 0.75 | FDPS (0.44) | SMN1; SMN2HIF1ACES1FDPSPTPN1 | |
| SCHEMBL454800 | 0.74 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ACES1FDPSCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | claimed |
| CN-119907695-A | Novel small gastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy | 慕尼黑工业大学 | 2025-04-29 | — | — | CN | disclosed |
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | disclosed |
| WO-2024253964-A2 | A COMPACT 7 MEV TO 11 MEV CYCLOTRON FOR MEDICAL ISOTOPES PRODUCTION | BEST ABT, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-2785445-A1 | PRODUCTION OF 18F- LABELLED COMPOUNDS COMPRISING HYDROLYTIC DEPROTECTION STEP AND SOLID PHASE EXTRACTION | GE Healthcare UK Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8722014-B2 | 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof | WASHINGTON UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013079578-A1 | PRODUCTION OF 18F- LABELLED COMPOUNDS COMPRISING HYDROLYTIC DEPROTECTION STEP AND SOLID PHASE EXTRACTION | GE HEALTHCARE LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-20100278732-A1 | 1H-[1, 2, 3] TRIAZOLE SUBSTITUTED AMINO ACIDS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2010-11-04 | — | — | US | disclosed |
| EP-1797029-A1 | METHOD OF DEPROTECTION | GE Healthcare Limited (GB) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006037950-A1 | METHOD OF DEPROTECTION | GE HEALTHCARE LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278732-A1 | 1H-[1, 2, 3] TRIAZOLE SUBSTITUTED AMINO ACIDS AND USES THEREOF | SLC7A1, SLC1A5, SLC1A3 | SMN1; SMN2 4022/4885HIF1A 1456/4885CES1 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.